Home Newsfeeds Wolfe Research Initiates Coverage On L3Harris Technologies with Peer Perform Rating

Wolfe Research Initiates Coverage On L3Harris Technologies with Peer Perform Rating

Wolfe Research analyst Myles Walton initiates coverage on L3Harris Technologies (NYSE:LHX) with a Peer Perform rating.

byBenzinga Newsdesk

October 11, 2022

1 minute read

Wolfe Research analyst Myles Walton initiates coverage on L3Harris Technologies (NYSE:LHX) with a Peer Perform rating.

Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational PRESent-3 Study Evaluating SerpinPC For The Treatment Of Hemophilia B With Inhibitors

By Benzinga Newsdesk

October 31, 8:06 AM

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject

CNTA

News

Coinbase Says In Series Of Tweets ‘We Won’t Comment On Every Event In Crypto, But For The Sake Of Clarity: Coinbase Has Zero Exposure To Genesis Trading’

By Benzinga Newsdesk

November 16, 1:39 PM

https://twitter.com/coinbase/status/1592934681770885121 1/ With the volatility of the crypto and overall markets, it’s important to reinforce that Coinbase has a sound risk management program and a strong capital

COIN

Marchex Q3 EPS $(0.01), Inline, Sales $13.197M Miss $13.50M Estimate

By Benzinga Newsdesk

November 3, 4:43 PM

Marchex (NASDAQ:MCHX) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $13.197M million which Missed the analyst consensus estimate of $13.50 million.

MCHX

News

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use Of FOTIVDA For Treatment Of Refractory Advanced Renal Cell Carcinoma

By Michael Horton

October 12, 4:09 PM

AVEO Oncology (NASDAQ:AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced today that, as disclosed on

AVEO

Wolfe Research Initiates Coverage On L3Harris Technologies with Peer Perform Rating

Related Posts

Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational PRESent-3 Study Evaluating SerpinPC For The Treatment Of Hemophilia B With Inhibitors

Coinbase Says In Series Of Tweets ‘We Won’t Comment On Every Event In Crypto, But For The Sake Of Clarity: Coinbase Has Zero Exposure To Genesis Trading’

Marchex Q3 EPS $(0.01), Inline, Sales $13.197M Miss $13.50M Estimate

U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use Of FOTIVDA For Treatment Of Refractory Advanced Renal Cell Carcinoma